Molecular study of Nucleophosmin 1(NPM1) gene in acute myeloid leukemia in Kurdish population

Othman, Galawezh; Mohammad, Nawsherwan Sadiq; Saeed, Chiman Hameed

doi:10.4314/ahs.v21i2.26

Cited by 6 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute leukemia is a term used to define the malignant transformation that affects the stem cell precursors of the myeloid lineage (red blood cells, while blood cells and platelets) and/or the lymphoid lineage (B and T lymphoid cells) which evolves rapidly due to the underlying genetic aberrations that induce the neoplastic alterations and clonal proliferation. [1][2][3] In order to accurately diagnose and classify AL, integrative multiple steps are crucial to be done which are clinical history and examination, morphological, cytochemical, immunophenotypic and cytogenetic and molecular analysis. The immunophenotyping by multi parametric FCM of the immature malignant blast population of AL is vital to determine the lineage of the blast cell and hence to classify AL.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of aberrant expression of CD markers in acute leukemia cells

kareem Shwani,

Sadiq Muhammad,

Hassan Hamza

2023

Zanco J Med Sci

View full text Add to dashboard Cite

Background and objective: Worldwide immunophenotyping by flow cytometry (FCM) in acute leukemia (AL) is the golden step in the diagnosis. It’s very common for acute leukemias to aberrantly express antigens or cluster of differentiation (CD) markers which are usually expressed in other lineages of the disease hence this study aimed at determining the prevalence of aberrancy in AL and to find out the frequency of each aberrant CD marker and their association with the clinic-hematological profile of the cases. Methods: Following history and clinical examination of enrolled patients, blood and/or bone marrow aspirate was drawn for morphological examination and immunophenotyping by FCM from 86 newly diagnosed acute leukemia cases then multiple steps procedure was applied followed by interpretation of the results. Results: The prevalence of aberrant phenotype was 46.5%. The proportional frequency of aberrant phenotype in acute myeloid leukemia (AML) was 41%, in B-acute lymphoblastic leukemia (B-ALL) was 48.8% and in T-acute lymphoblastic leukemia (T-ALL) was 66.6%. The commonest aberrant CD markers in AML were CD22 and CD2, in B-ALL were CD66c and CD13 while in T-ALL were CD13 and CD33. The aberrant phenotype harbored lower white blood cell (WBC) count and blast percentage in PB, also splenomegaly was more frequent in lymphoid positive (Ly+) AML and myeloid positive (My+) T-ALL while in B-ALL, splenomegaly was more frequent in myeloid negative (My-) B-ALL. Conclusion: Aberrant phenotype prevalence in our study sample was comparable to other studies, considerable frequency of aberrant markers is present in cases of AL and some variations exist regarding the clinical and hematological profile of the aberrant group.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of aberrant expression of CD markers in acute leukemia cells

kareem Shwani,

Sadiq Muhammad,

Hassan Hamza

2023

Zanco J Med Sci

View full text Add to dashboard Cite

show abstract

“…We have several oncology papers. First, Uganda authors 20 have written on ‘detecting subclinical anthracycline therapy related cardiac dysfunction’; while Ghanaian workers bring to us theirs on ‘awareness and knowledge about prostate cancer among male teachers.’ 21 Then we have several papers on potential anticancer activity of on selected herbs 22 , 23 ; followed by a case report 24 on ‘transient bone marrow hypoplasia preceding T-Cell acute lymphoblastic leukemia.’ We end this section on cancer with a molecular study on nucleophosmin 1(NPM1) gene in acute myeloid leukemia 25 .…”

mentioning

confidence: 99%